Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-finding trial of NNC0174-0833 for weight management
2018-001945-14Phase 2Unknown
- Sponsor
- Novo Nordisk
- Start
- Oct 2018
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cagrilintide in obesity and Overweight (3 arms), sponsored by Novo Nordisk. Primary endpoint: Change in body weight (%). Status: unknown.
02
Drugs
cagrilintide
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on 2018-001945-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001945-14.